- Home
- PHT vs THRD Comparison
PHT vs THRD Comparison
Compare PHT & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHT
- THRD
- Stock Information
- Founded
- PHT 2002
- THRD 2019
- Country
- PHT United States
- THRD United States
- Employees
- PHT N/A
- THRD N/A
- Industry
- PHT Investment Managers
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- PHT Finance
- THRD Health Care
- Exchange
- PHT Nasdaq
- THRD Nasdaq
- Market Cap
- PHT 237.1M
- THRD 238.7M
- IPO Year
- PHT N/A
- THRD 2022
- Fundamental
- Price
- PHT $8.12
- THRD $5.43
- Analyst Decision
- PHT
- THRD Hold
- Analyst Count
- PHT 0
- THRD 3
- Target Price
- PHT N/A
- THRD $5.00
- AVG Volume (30 Days)
- PHT 85.5K
- THRD 225.7K
- Earning Date
- PHT 01-01-0001
- THRD 08-07-2025
- Dividend Yield
- PHT 8.76%
- THRD N/A
- EPS Growth
- PHT N/A
- THRD N/A
- EPS
- PHT 0.98
- THRD N/A
- Revenue
- PHT N/A
- THRD N/A
- Revenue This Year
- PHT N/A
- THRD N/A
- Revenue Next Year
- PHT N/A
- THRD N/A
- P/E Ratio
- PHT $7.71
- THRD N/A
- Revenue Growth
- PHT N/A
- THRD N/A
- 52 Week Low
- PHT $6.41
- THRD $3.18
- 52 Week High
- PHT $7.60
- THRD $16.02
- Technical
- Relative Strength Index (RSI)
- PHT 65.94
- THRD 65.57
- Support Level
- PHT $8.05
- THRD $5.40
- Resistance Level
- PHT $8.05
- THRD $5.45
- Average True Range (ATR)
- PHT 0.06
- THRD 0.04
- MACD
- PHT -0.00
- THRD -0.02
- Stochastic Oscillator
- PHT 83.33
- THRD 25.00
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.